Danielle B. CohenKuzani MbenderaHendramoorthy MaheswaranMavuto MukakaHelen MangochiLinna PhiriJason MadanGeraint DaviesElizabeth CorbettBertel SquireMalawi-Liverpool-Wellcome Trust Clinical Research ProgrammeLondon School of Hygiene & Tropical MedicineUniversity of OxfordThe University of WarwickLiverpool School of Tropical MedicineUniversity of LiverpoolMahidol UniversityUniversity of SheffieldNational TB Control Programme2020-01-272020-01-272020-01-01Thorax. Vol.75, No.1 (2020), 64-7114683296004063762-s2.0-85074491840https://repository.li.mahidol.ac.th/handle/123456789/49669© 2020 Author(s) (or their employer(s)). Re-use permitted under CC BY. Published by BMJ. Background People with recurrent or drug-resistant TB require long courses of intramuscular injections. We evaluate a novel system in which patient-nominated lay carers were trained to deliver intramuscular injections to patients in their own homes. Methods A pragmatic, individually randomised non-inferiority trial was conducted at two hospitals in Malawi. Adults starting TB retreatment were recruited. Patients randomised to the intervention received home-based care from patient-nominated lay people trained to deliver intramuscular streptomycin. Patients receiving standard care were admitted to hospital for 2 months of streptomycin. The primary outcome was successful treatment (alive and on treatment) at the end of the intervention. Results Of 456 patients screened, 204 participants were randomised. The trial was terminated early due to futility. At the end of the intervention, 97/101 (96.0%) in the hospital arm were still alive and on treatment compared with 96/103 (93.2%) in the home-based arm (risk difference -0.03 (95% CI -0.09 to 0.03); p value 0.538). There were no differences in the proportion completing 8 months of anti-TB treatment; or the proportion experiencing 2-month sputum culture conversion. The mean cost of hospital-based management was US$1546.3 per person, compared to US$729.2 for home-based management. Home-based care reduced risk of catastrophic household costs by 84%. Conclusions Although this trial failed to meet target recruitment, the available data demonstrate that training patient-nominated lay people has potential to provide a feasible solution to the operational challenges associated with delivering long-term-injectable drugs to people with recurrent or drug-resistant TB in resource-limited settings, and substantially reduce costs. Further data under operational conditions are required. Trial registration number ISRCTN05815615.Mahidol UniversityMedicineArticleSCOPUS10.1136/thoraxjnl-2018-212675